Full Press Release Details
Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023.
ZYME
Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023
Key Takeaway: Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023
Price reaction · baseline $9.55 (2023-12-07 close) · hit after-hours · clean, no other ZYME news in the window
day 0 close · peak
-2.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers